Clinical Trials Logo

Filter by:
NCT ID: NCT00150449 Completed - Anxiety Neuroses Clinical Trials

Determine Long-Term Safety and Tolerability of Pregabalin in Patients With Anxiety Disorders.

Start date: January 2001
Phase: Phase 3
Study type: Interventional

Determine long-term safety and tolerability of pregabalin in patients with anxiety disorders.

NCT ID: NCT00150293 Completed - Clinical trials for Seizure Disorder, Partial

Evaluation of Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

Start date: March 2002
Phase: Phase 3
Study type: Interventional

To determine long-term safety and efficacy of pregabalin in patients with partial seizures.

NCT ID: NCT00149409 Completed - Clinical trials for Chronic Heart Failure

Omega-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Severe Chronic Heart Failure

Start date: September 2005
Phase: Phase 2/Phase 3
Study type: Interventional

To investigate whether n3-fatty acids have beneficial effects in chronic heart failure as regards circulatory function.

NCT ID: NCT00148889 Completed - Cervical Dystonia Clinical Trials

Double-blind, Multicenter Study to Assess the Efficacy of Bilateral Pallidal Stimulation in Patients With Medically Refractory Primary Cervical Dystonia

Start date: July 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the efficacy and safety of bilateral pallidal stimulation in patients with medically refractory primary cervical dystonia.

NCT ID: NCT00148798 Completed - Clinical trials for Non Small Cell Lung Cancer (NSCLC)

Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)

FLEX
Start date: October 2004
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to investigate the efficacy of cetuximab in combination with chemotherapy in comparison to chemotherapy alone in patients with advanced non small cell lung cancer who did not received prior chemotherapy. Overall survival will be taken as primary measure of efficacy.

NCT ID: NCT00148512 Completed - Parkinson Disease Clinical Trials

A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations

Start date: March 2003
Phase: Phase 2
Study type: Interventional

The primary objective of this exploratory study is to investigate the efficacy and safety of tesofensine in daily doses (from 0.125 mg to 1.0 mg) in comparison to placebo, over a 14-week treatment period in levodopa treated Parkinson patients with motor fluctuations.

NCT ID: NCT00147602 Completed - Clinical trials for Cardiovascular Disease

Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke

SPARCL
Start date: November 1998
Phase: Phase 4
Study type: Interventional

To determine whether Lipitor reduces stroke, compared to placebo in patients who have had a previous stroke or transient ischemic attack.

NCT ID: NCT00147381 Completed - Clinical trials for Kidney Transplantation

Effectiveness and Safety of Campath in Combination With Tacrolimus Monotherapy to Prevent Kidney Graft Rejection

Start date: January 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether Campath following Tacrolimus monotherapy is more effective in the prevention of renal graft rejection (considering an acute rejection rate of 5% for Campath-1H/Tacrolimus and of 22% for Tacrolimus/MMF/Steroids).

NCT ID: NCT00147199 Completed - Clinical trials for Pulmonary Hypertension

Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)

TRIUMPH
Start date: June 2005
Phase: Phase 3
Study type: Interventional

This is a double-blind placebo-controlled clinical investigation into the efficacy and tolerability of inhaled treprostinil in patients with severe pulmonary arterial hypertension. The primary outcome is the change in 6-minute walk distance from baseline to week 12.

NCT ID: NCT00147004 Completed - Shock, Septic Clinical Trials

Corticosteroid Therapy of Septic Shock - Corticus

Corticus
Start date: March 2002
Phase: Phase 3
Study type: Interventional

The purpose of the study is to determine whether steroids decrease 28-day mortality in patients with septic shock.